Exploring the landscape of immunotherapy approaches in sarcomas.
bone sarcoma
checkpoint inhibitors
immunotherapy
sarcoma
soft tissue sarcoma
undifferentiated pleomorphic sarcoma UPS
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2022
2022
Historique:
received:
14
10
2022
accepted:
19
12
2022
entrez:
23
1
2023
pubmed:
24
1
2023
medline:
24
1
2023
Statut:
epublish
Résumé
Sarcomas comprise a heterogenous group of malignancies, of more than 100 different entities, arising from mesenchymal tissue, and accounting for 1% of adult malignancies. Surgery, radiotherapy and systemic therapy constitute the therapeutic armamentarium against sarcomas, with surgical excision and conventional chemotherapy, remaining the mainstay of treatment for local and advanced disease, respectively. The prognosis for patients with metastatic disease is dismal and novel therapeutic approaches are urgently required to improve survival outcomes. Immunotherapy, is a rapidly evolving field in oncology, which has been successfully applied in multiple cancers to date. Immunomodulating antibodies, adoptive cellular therapy, cancer vaccines, and cytokines have been tested in patients with different types of sarcomas through clinical trials, pilot studies, retrospective and prospective studies. The results of these studies regarding the efficacy of different types of immunotherapies in sarcomas are conflicting, and the application of immunotherapy in daily clinical practice remains limited. Additional clinical studies are ongoing in an effort to delineate the role of immunotherapy in patients with specific sarcoma subtypes.
Identifiants
pubmed: 36686827
doi: 10.3389/fonc.2022.1069963
pmc: PMC9853527
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
1069963Informations de copyright
Copyright © 2023 Pilavaki, Panagi, Arifi, Jones, Stylianopoulos and Constantinidou.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Oncoimmunology. 2017 Apr 12;6(5):e1312239
pubmed: 28638739
J Clin Oncol. 2008 Feb 1;26(4):633-8
pubmed: 18235123
JAMA Oncol. 2022 May 1;8(5):740-747
pubmed: 35357396
Endocr Relat Cancer. 2017 Dec;24(12):T283-T295
pubmed: 28754821
Clin Cancer Res. 2017 Jun 15;23(12):2972-2980
pubmed: 28007774
J Clin Oncol. 2010 Jul 10;28(20):3284-91
pubmed: 20547982
Science. 2011 Mar 25;331(6024):1565-70
pubmed: 21436444
Eur J Cancer. 2021 Jul;152:165-182
pubmed: 34107450
Clin Sarcoma Res. 2016 Dec 30;6:24
pubmed: 28042471
N Engl J Med. 2014 Dec 4;371(23):2189-2199
pubmed: 25409260
Sarcoma. 2013;2013:868973
pubmed: 24369450
Cancers (Basel). 2020 Jul 11;12(7):
pubmed: 32664595
BMC Cancer. 2022 Jan 12;22(1):56
pubmed: 35022029
J Clin Oncol. 2015 Sep 1;33(25):2780-8
pubmed: 26014293
Sarcoma. 2013;2013:168145
pubmed: 23554566
JAMA. 2020 Apr 7;323(13):1266-1276
pubmed: 32259228
Cancer. 2017 May 1;123(9):1576-1584
pubmed: 28241093
J Immunother Cancer. 2019 Aug 8;7(1):213
pubmed: 31395100
J Clin Oncol. 2016 Nov 10;34(32):3898-3905
pubmed: 27621408
South Asian J Cancer. 2016 Jan-Mar;5(1):15-9
pubmed: 27169114
Cytotherapy. 2013 Dec;15(12):1563-70
pubmed: 24094496
Lancet Oncol. 2017 Nov;18(11):1493-1501
pubmed: 28988646
Lancet Oncol. 2019 Jun;20(6):837-848
pubmed: 31078463
J Immunother Cancer. 2021 Aug;9(8):
pubmed: 34380663
Int J Radiat Oncol Biol Phys. 2002 Mar 15;52(4):1032-40
pubmed: 11958899
J Immunother Cancer. 2021 Jul;9(7):
pubmed: 34301809
Nat Immunol. 2002 Nov;3(11):991-8
pubmed: 12407406
Future Oncol. 2020 Jun;16(17):1211-1223
pubmed: 32396026
Thorac Cancer. 2019 May;10(5):1031-1035
pubmed: 30900824
Clin Cancer Res. 2015 Mar 1;21(5):1019-27
pubmed: 25538264
Pediatr Transplant. 2009 Sep;13(6):746-53
pubmed: 19067917
Lancet Oncol. 2018 Mar;19(3):416-426
pubmed: 29370992
Cancer. 1984 Feb 15;53(4):896-905
pubmed: 6692292
Front Immunol. 2021 Dec 03;12:775761
pubmed: 34925348
Cancer Res. 2001 Dec 1;61(23):8513-9
pubmed: 11731436
BMC Cancer. 2020 Jun 5;20(1):527
pubmed: 32503455
Ann Oncol. 2021 Dec;32(12):1520-1536
pubmed: 34500044
Nature. 2020 Jan;577(7791):556-560
pubmed: 31942077
Immunotherapy. 2020 Dec;12(18):1303-1312
pubmed: 32967520
Lancet Oncol. 2012 Oct;13(10):1045-54
pubmed: 22954508
Med Oncol. 2017 Nov 1;34(12):191
pubmed: 29094224
Hum Pathol. 2015 Mar;46(3):357-65
pubmed: 25540867
J Immunother Cancer. 2020 Nov;8(2):
pubmed: 33203665
Cancer Genet Cytogenet. 2004 Apr 1;150(1):50-6
pubmed: 15041223
JAMA Oncol. 2020 Mar 1;6(3):402-408
pubmed: 31971541
Br J Radiol. 2013 Oct;86(1030):20130439
pubmed: 24014066
Cancer Immunol Res. 2019 Aug;7(8):1237-1243
pubmed: 31171504
Nat Commun. 2022 Jun 16;13(1):3477
pubmed: 35710741
Clin Transl Oncol. 2012 Apr;14(4):271-9
pubmed: 22484634
J Clin Oncol. 2016 Dec;34(34):4102-4109
pubmed: 27863197
J Vasc Interv Radiol. 2021 Dec;32(12):1688-1694
pubmed: 34478852
Oncologist. 2021 May;26(5):e847-e858
pubmed: 33594772
Immunotherapy. 2020 Jun;12(9):641-652
pubmed: 32489121
J Clin Oncol. 2011 Jun 20;29(18):2528-33
pubmed: 21606430
Cancer. 2017 Sep 1;123(17):3291-3304
pubmed: 28463396
Ann Surg. 1999 May;229(5):602-10; discussion 610-2
pubmed: 10235518
Adv Exp Med Biol. 2017;1036:51-64
pubmed: 29275464
Clin Cancer Res. 2022 Jun 1;28(11):2306-2312
pubmed: 35349638
Pathobiology. 2015 Feb 28;82(1):36-42
pubmed: 25766089
J Clin Oncol. 2017 Oct 10;35(29):3322-3329
pubmed: 28809608
Surg Clin North Am. 2016 Oct;96(5):901-14
pubmed: 27542634
Cancer. 2017 Sep 1;123(17):3285-3290
pubmed: 28440953
Curr Treat Options Oncol. 2019 Jan 24;20(1):6
pubmed: 30675651
Anticancer Res. 2013 Dec;33(12):5495-500
pubmed: 24324087
N Engl J Med. 2018 Apr 05;378(14):1277-1290
pubmed: 29562145
Cancer. 1981 Oct 1;48(7):1569-81
pubmed: 6945143
J Clin Oncol. 2017 Oct 20;35(30):3433-3439
pubmed: 28854066
J Cancer. 2018 Apr 19;9(10):1773-1781
pubmed: 29805703
Clin Cancer Res. 2022 May 2;28(9):1765-1772
pubmed: 34965951
Nat Med. 2022 Jun;28(6):1199-1206
pubmed: 35618839
Lancet Oncol. 2017 Dec;18(12):1600-1609
pubmed: 29129441
Int J Cancer. 2010 Feb 15;126(4):909-18
pubmed: 19728336
Diagn Mol Pathol. 1996 Sep;5(3):214-9
pubmed: 8866236
Br J Cancer. 2017 Jun 27;117(1):33-40
pubmed: 28588322
Lancet Oncol. 2022 Sep;23(9):1156-1166
pubmed: 35934010
Br J Cancer. 2003 Jun 16;88(12):1925-31
pubmed: 12799638
ESMO Open. 2020 Aug;5(4):
pubmed: 32847839
J Immunother Cancer. 2020 Mar;8(1):
pubmed: 32179633
Br J Radiol. 2012 Nov;85(1019):e1127-33
pubmed: 22806620
Oncoimmunology. 2020 Nov 19;9(1):1847846
pubmed: 33312760
Sarcoma. 2004;8(4):123-7
pubmed: 18521406
J Immunother Cancer. 2021 May;9(5):
pubmed: 33963013
Oncologist. 2018 Feb;23(2):234-242
pubmed: 28860410
Clin Cancer Res. 2021 Dec 1;27(23):6424-6431
pubmed: 34475102
Cancer Rep (Hoboken). 2021 Apr;4(2):e1327
pubmed: 33314769
J Clin Oncol. 2001 Mar 1;19(5):1238-47
pubmed: 11230464
Nat Med. 2020 Feb;26(2):181-187
pubmed: 32042194
Lancet. 2012 May 19;379(9829):1879-86
pubmed: 22595799
Cancer. 1973 Jul;32(1):1-8
pubmed: 4716773
Pediatr Blood Cancer. 2018 Sep;65(9):e27227
pubmed: 29923370
Pathologica. 2021 Apr;113(2):70-84
pubmed: 33179614
Gynecol Oncol. 2008 May;109(2):174-81
pubmed: 18314182
J Transl Med. 2021 Apr 26;19(1):173
pubmed: 33902630
J Bone Oncol. 2020 Oct 16;25:100332
pubmed: 33145154
Br J Cancer. 1996 Aug;74(3):453-5
pubmed: 8695363
Cancer Immunol Immunother. 2015 Oct;64(10):1251-60
pubmed: 26105625
Front Oncol. 2019 Nov 14;9:1169
pubmed: 31799177
Ann Surg Oncol. 2014 Aug;21(8):2484-9
pubmed: 24756814
J Clin Oncol. 1996 Mar;14(3):859-68
pubmed: 8622034
Cancer Sci. 2013 Oct;104(10):1285-94
pubmed: 23829867
J Clin Oncol. 2016 Mar 10;34(8):786-93
pubmed: 26371143
Int J Radiat Oncol Biol Phys. 2005 Apr 1;61(5):1446-53
pubmed: 15817349
Cytotherapy. 2012 Jan;14(1):80-90
pubmed: 21942841
Cancer Manag Res. 2021 Dec 03;13:8999-9005
pubmed: 34887682
N Engl J Med. 2018 May 31;378(22):2078-2092
pubmed: 29658856
Clin Cancer Res. 2019 Apr 1;25(7):2096-2108
pubmed: 30573690
Cancers (Basel). 2021 Oct 29;13(21):
pubmed: 34771615
Cancer. 2020 Jul 1;126(13):3002-3012
pubmed: 32315454
Lancet. 2016 Apr 16;387(10028):1629-37
pubmed: 26874885
J Clin Oncol. 2004 Dec 1;22(23):4787-94
pubmed: 15570080
J Immunother Cancer. 2021 Jul;9(7):
pubmed: 34301811
Lancet Oncol. 2017 Sep;18(9):1182-1191
pubmed: 28734759
Anticancer Res. 2020 Dec;40(12):7095-7100
pubmed: 33288608
N Engl J Med. 2017 Oct 12;377(15):1409-1412
pubmed: 29020592
Am J Surg Pathol. 2016 Aug;40(8):1133-42
pubmed: 27158757
Eur J Cancer. 2019 Sep;119:151-157
pubmed: 31442817
Ann Transl Med. 2021 Feb;9(4):339
pubmed: 33708966
Clin Cancer Res. 2016 Jul 1;22(13):3182-91
pubmed: 26823601
J Clin Oncol. 2007 Jul 1;25(19):2755-63
pubmed: 17602081
Ann Oncol. 2021 Nov;32(11):1348-1365
pubmed: 34303806
J Clin Oncol. 2015 May 20;33(15):1688-96
pubmed: 25800760
Immunotherapy. 2017 May;9(6):499-506
pubmed: 28472902
Cancer Lett. 2020 Jun 1;479:54-60
pubmed: 31634526
JAMA Oncol. 2020 Nov 01;6(11):1778-1782
pubmed: 32910151
Cancer Lett. 2018 Apr 10;419:210-221
pubmed: 29414305
Eur J Cancer. 2013 Feb;49(3):684-95
pubmed: 23079473
J Immunother Cancer. 2019 Oct 24;7(1):276
pubmed: 31651363
JCO Precis Oncol. 2021 Nov;5:1-5
pubmed: 34994591
Pharmacol Ther. 2019 Feb;194:84-106
pubmed: 30268773
Lancet Oncol. 2018 Nov;19(11):1480-1492
pubmed: 30361170
N Engl J Med. 2017 Jun 22;376(25):2415-2426
pubmed: 28636851
Ann Surg Oncol. 1998 Jun;5(4):356-60
pubmed: 9641458
J Immunol Res. 2020 Oct 01;2020:7890985
pubmed: 33062726
PLoS One. 2013 Dec 11;8(12):e82870
pubmed: 24349382
JAMA Oncol. 2018 Jan 01;4(1):93-97
pubmed: 28662235
Lancet. 2019 May 4;393(10183):1819-1830
pubmed: 30955977
Oncologist. 2018 Jan;23(1):71-83
pubmed: 28935774
J Immunother Cancer. 2021 Mar;9(3):
pubmed: 33762319
Mol Ther. 2016 Aug;24(8):1478-83
pubmed: 27109631
Diagnostics (Basel). 2022 Mar 17;12(3):
pubmed: 35328286
Lancet Oncol. 2014 Apr;15(4):415-23
pubmed: 24618336
Clin Cancer Res. 2020 Dec 15;26(24):6445-6452
pubmed: 33046518
Mol Ther. 2015 Mar;23(3):602-8
pubmed: 25531693